A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

ClinicalTrials.gov ID: NCT07221162

Public ClinicalTrials.gov record NCT07221162. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 4, 2026, 8:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults

Study identification

NCT ID: NCT07221162
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 140 participants

Conditions and interventions

Conditions

COVID-19

Interventions

Aluminum Hydroxide Suspension Drug
Boost-2867 Biological
CpG 7909 Biological
Sodium Chloride, 0.9% Other

Drug · Biological · Other

Eligibility (public fields only)

Age range: 18 Years to 64 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 4, 2025
Primary completion: Nov 23, 2026
Completion: Nov 23, 2026
Last update posted: Apr 30, 2026

2025 – 2026

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine	San Francisco	California	94110	Recruiting
Center for Immunization Research, Johns Hopkins Bloomberg School Public Health	Baltimore	Maryland	21205	Recruiting
Saint Louis University Center for Vaccine Development	St Louis	Missouri	63104-1015	Recruiting
University of Rochester Medical Center - Vaccine Research Unit	Rochester	New York	14642-0001	Recruiting
Duke Vaccine and Trials Unit	Durham	North Carolina	27703	Recruiting
University of Pittsburgh - Medicine - Infectious Diseases	Pittsburgh	Pennsylvania	15213	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting
Kaiser Permanente Washington Health Research Institute	Seattle	Washington	98101-1466	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07221162, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07221162 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →